Cellanyx’s lead test is an LDT risk stratification test designed to address the clinical challenges in prostate cancer diagnosis and management. The company has published clinical proof of concept studies with the test and is positioned to begin a prospective clinical trial to demonstrate clinical utility in patients undergoing biopsies that is expected to provide the foundation for its commercial introduction. Risk stratification tests for Stage 0 breast cancer, and other solid tumors, including renal, bladder and non-small cell lung, are in earlier stages of development.